METIS TECHBIO-P (07666) rose nearly 6% in morning trading. As of press time, it was up 3.31% at HK$7.495, with a turnover of HK$10.5836 million.
On the news front, METIS TECHBIO announced that in order to promote business development and enhance the company's overall competitive strength, it has officially launched preparatory work related to an A-share listing. The company has engaged a pre-listing tutoring institution and will subsequently submit a tutoring filing application to regulatory authorities in accordance with regulations. If the process proceeds smoothly, METIS TECHBIO is expected to establish an "A+H" capital structure.
According to public information, METIS TECHBIO has successively formed a strategic partnership with Luye Pharma and, through its subsidiary Metis Life, signed a joint venture agreement with Joinn Biologics to respectively advance the R&D and transformation of AI drug delivery technology and the construction of an mRNA R&D and manufacturing platform. Combined with its recent collaboration with Eli Lilly, the company has established multi-party cooperative relationships across delivery technology R&D, industrialization and transformation, and other segments.
Guohai Securities believes that the resources and capabilities of different partners are expected to complement each other, driving the extension of platform technology toward practical R&D and industrialization applications. Going forward, key focuses include the progress of collaborative projects, new partnerships, and revenue recognition.
Comments